Aeglea BioTherapeutics Announces 1-Year Data for Pegzilarginase in Patients with Arginase 1 Deficiency at the 6th Congress of the European Academy of Neurology
May 26, 2020 08:30 ET
|
Aeglea BioTherapeutics, Inc.
Pegzilarginase Showed Durable Clinical Response at 56 Week Analysis All Patients Demonstrated a Marked and Sustained Reduction in Plasma Arginine Favorable Safety Profile, Consistent with...